DK2310357T3 - Kaliumionkanalmodulatorer og anvendelser deraf - Google Patents

Kaliumionkanalmodulatorer og anvendelser deraf Download PDF

Info

Publication number
DK2310357T3
DK2310357T3 DK09785362T DK09785362T DK2310357T3 DK 2310357 T3 DK2310357 T3 DK 2310357T3 DK 09785362 T DK09785362 T DK 09785362T DK 09785362 T DK09785362 T DK 09785362T DK 2310357 T3 DK2310357 T3 DK 2310357T3
Authority
DK
Denmark
Prior art keywords
calcium channel
channel modulators
modulators
calcium
channel
Prior art date
Application number
DK09785362T
Other languages
Danish (da)
English (en)
Inventor
Simon David Edwards
Richard Edward Armer
Meriel Ruth Kimberley
Nawaz Mohammed Khan
Original Assignee
Ramot At Tel Aviv Univ Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel Aviv Univ Limited filed Critical Ramot At Tel Aviv Univ Limited
Application granted granted Critical
Publication of DK2310357T3 publication Critical patent/DK2310357T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
DK09785362T 2008-07-22 2009-07-20 Kaliumionkanalmodulatorer og anvendelser deraf DK2310357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0813403.3A GB0813403D0 (en) 2008-07-22 2008-07-22 Potassium ion channel modulators & uses thereof
PCT/GB2009/050887 WO2010010380A1 (en) 2008-07-22 2009-07-20 Potassium ion channel modulators & uses thereof

Publications (1)

Publication Number Publication Date
DK2310357T3 true DK2310357T3 (da) 2019-11-25

Family

ID=39737453

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09785362T DK2310357T3 (da) 2008-07-22 2009-07-20 Kaliumionkanalmodulatorer og anvendelser deraf

Country Status (7)

Country Link
US (2) US9464052B2 (enExample)
EP (1) EP2310357B1 (enExample)
JP (1) JP2011529037A (enExample)
CN (1) CN102159535A (enExample)
DK (1) DK2310357T3 (enExample)
GB (1) GB0813403D0 (enExample)
WO (1) WO2010010380A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
US8624063B2 (en) 2009-06-30 2014-01-07 Wisconsin Alumni Research Foundation Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
KR101599300B1 (ko) * 2012-03-14 2016-03-03 시노켐 코포레이션 치환 디페닐아민 화합물 및 항종양제로서의 용도
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
US10995097B2 (en) * 2016-03-11 2021-05-04 The Board Of Trustees Of The University Of Illinois Small molecules active against gram-negative bacteria
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
JP7448472B2 (ja) * 2017-10-09 2024-03-12 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド カリウムイオンチャネル及びｔｒｐｖ１チャネルのモジュレーター、並びにその使用
US10526278B2 (en) 2017-10-19 2020-01-07 Wisconsin Alumni Research Foundation Inhibitors of quorum sensing receptor LasR
EP4025300A1 (en) * 2019-09-03 2022-07-13 Salzman Group Ltd. Atp-regulated potassium channel openers comprising guanidine and uses thereof
IL328371A (en) * 2019-09-17 2026-07-01 Knopp Biosciences Llc Usage methods for KV7 channel operators
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
WO2022157686A1 (en) * 2021-01-22 2022-07-28 Ildong Pharmaceutical Co., Ltd. Inhibitors of anoctamin 6 protein and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
EP4308544A4 (en) * 2021-03-19 2025-04-30 Xyzagen, Inc. PRODRUGS OF KV7 CHANNEL OPENERS
WO2023118507A2 (en) 2021-12-22 2023-06-29 Augustine Therapeutics Compounds and use thereof as hdac6 inhibitors
WO2023139581A1 (en) * 2022-01-18 2023-07-27 Bsense Bio Therapeutics Ltd. Modulators of a potassium channel and of trpv1 channel and uses thereof
WO2024050389A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators and nmda receptor antagonists
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1882286A (en) 1929-07-17 1932-10-11 Gen Aniline Works Inc Arylamides of meta-hydroxy-diarylamine-carboxylic acids and process of making same
BE590607A (enExample) 1960-02-24
US3413313A (en) 1964-06-18 1968-11-26 Parke Davis & Co Anthranilic acid compounds and methods for their production
US4181519A (en) 1977-01-21 1980-01-01 Shell Oil Company Diphenylamine derivative herbicides
CA1087186A (en) 1977-01-21 1980-10-07 Kurt H. G. Pilgram Cycloalkane-carboxanilides
ZA865090B (en) 1985-07-22 1988-02-24 Riker Laboratories Inc Substituted di-t-butylphenols
IL86462A (en) 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
JPH03278050A (ja) 1990-03-27 1991-12-09 Konica Corp ハロゲン化銀写真感光材料
JPH0473190A (ja) 1990-07-16 1992-03-09 Konica Corp 感熱転写記録材料
EP0659047A1 (en) 1992-09-09 1995-06-28 E.I. Du Pont De Nemours And Company Herbicidal benzene compounds
ATE344791T1 (de) * 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
US6268387B1 (en) 1997-12-23 2001-07-31 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
JP2003527379A (ja) * 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
FR2836917B1 (fr) * 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
EP1553932A2 (en) * 2002-10-21 2005-07-20 Ramot at Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
AU2004258841B8 (en) 2003-06-05 2010-01-07 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
KR101291483B1 (ko) 2004-12-15 2013-07-30 돔페 파르마 에스.피.에이. 2-아릴프로피온산 유도체 및 이들을 함유하는 제약학적조성물
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
TWI396543B (zh) 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物
BRPI0611596A2 (pt) 2005-06-21 2010-09-21 Mitsui Chemicals Inc derivado de amina e inseticida contendo o mesmo
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
CA2628863A1 (en) 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof

Also Published As

Publication number Publication date
WO2010010380A1 (en) 2010-01-28
US20110245250A1 (en) 2011-10-06
EP2310357B1 (en) 2019-09-11
JP2011529037A (ja) 2011-12-01
US20160374969A1 (en) 2016-12-29
US9675567B2 (en) 2017-06-13
CN102159535A (zh) 2011-08-17
EP2310357A1 (en) 2011-04-20
GB0813403D0 (en) 2008-08-27
US9464052B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
NL300962I1 (nl) patiromer sorbitex calcium
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2268562T3 (da) Shuttlestation og shuttle-kanallager
DK2376519T3 (da) TGR5-modulatorer og fremgangsmåde til anvendelse deraf
DE602008002815D1 (de) Knochenverankerungsvorrichtung
DE602007007758D1 (de) Knochenverankerungsvorrichtung
DE602007007466D1 (de) Knochenverankerungsvorrichtung
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK3614595T3 (da) Fremgangsmåde og indretning til forbedrede statusrapporter
EP2157979A4 (en) CALCIUM CHANNEL PROTEINS AND USE THEREOF
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
SMT201300040B (it) Analoghi piridonici e piridazonici come modulatoridi gpr119
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
FI20085334A0 (fi) Harjoitusmenetelmä ja -järjestelmä
DK2220320T3 (da) Forseglet enhed og mellemstykke
DK2162402T3 (da) Membranbåret biofilmanordning og fremgangsmåde
DK2239414T3 (da) Tætningsanordning
EP2129864A4 (en) DRILL CABLE TRACTOR DEVICE
DK2185552T3 (da) Dipeptoid-prodrugs og anvendelse heraf
FI20085565A7 (fi) Tiivistyslaite
DK2086213T3 (da) Billedlæseapparat og billeddannelseapparat
DK2356648T3 (da) Forseglingsindretning
DE602009001221D1 (de) Abdichtungsvorrichtung
BRPI0815203A2 (pt) gel contendo pirfenidona